OmniAb Q1 2024 revenue drops to $3.8M; net loss widens to $19.0M

OmniAb, Inc.

2024-Q1 EPS reported -$0.19 revenue$3,801,000

Revenue $3.8M vs $16.9M YoY; net loss $19.0M ($0.19/share) vs $6.1M ($0.06/share) loss.
Cash and short-term investments $69.0M; expects 2024 cash use similar to 2023 excluding $35M milestone.
Signed three new license agreements; 80 active partners, 327 active programs, 31 in clinic.
Pipeline: batoclimab MG Phase 3 topline H2 2024; IMVT-1402 plans 4-5 registrational programs.
Guidance: 2024 operating expense flat vs 2023; cash use substantially lower in 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OmniAb, Inc. reported the three months ended March 31, 2024 results: revenue $3.8 million, net income $19.0 million net loss, EPS $0.19 per share loss.

Period: the three months ended March 31, 2024
Revenue: $3.8 million
Net income: $19.0 million net loss
EPS: $0.19 per share loss
Result: reported results

Exact text from the filing

to continued progress by our partners and expansion of our technology as the year progresses.” First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $3.8 million, compared with $16.9 million for the same period in 2023, with the decrease primarily due to the recognition in the 2023 period of a $10 million milestone related to the first

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OmniAb, Inc. reported the first quarter of 2024 results: revenue $3.8 million, net income $19.0 million net loss, EPS $0.19 per share loss.

Period: the first quarter of 2024
Revenue: $3.8 million
Net income: $19.0 million net loss
EPS: $0.19 per share loss
Result: reported results

Exact text from the filing

to continued progress by our partners and expansion of our technology as the year progresses.” First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $3.8 million, compared with $16.9 million for the same period in 2023, with the decrease primarily due to the recognition in the 2023 period of a $10 million milestone related to the first

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

OmniAb, Inc. filing history →

Source: SEC EDGAR

accession 0001846253-24-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.